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HealthcareIn this issue of the Journal, Schwaneberg et al. present a large
retrospective German cohort study which assesses the trends
in treatment patterns and comorbidities in patientswith lower
extremity peripheral artery disease (PAD).1 The authors
demonstrate an increasing number of peripheral vascular in-
terventions (PVI), and fewer major amputations. Of note,
these interventions were performed in sicker and older pa-
tients, with an increased disease related reimbursement cost.
Interestingly, while the estimated incident cases of PAD
among the cohort slightly decreased, a significant increase of
prevalent PAD cases, numbers of hospitalisations and PVI was
observed. The interpretation of these results is a reduction of
new cases combined with prolonged periods of chronic disease,
through a higher life expectancy and repeated revascularisa-
tions. Considering the incidence estimations, the study has a
limitedobservation timeanda limitednumberofpeople insured
by the company, and it remains unclearwhether the decrease of
incident cases could also be the consequence of fewer people
being at risk at the end of the timeframe. It should be remem-
bered that claims data from an insurance database are not truly
population based. Even with this limitation in mind, the authors
have demonstrated an increasing number of PVI performed to
increasingly ill andolderpatientswith rising costs.Theyhavealso
demonstrated, without doubt, an increasing trend of relevant
cardiovascular comorbidities in patients with PAD, such as hy-
pertension, cardiac dysrhythmia, and renal failure.
A recent epidemiological study by Song et al.2 has sug-
gested that in 2015, PAD affected around 236 million
people worldwide with a global prevalence of 5.6%.
Advanced age, smoking, hypertension, diabetes, and
concomitant cardiovascular diseases were confirmed to be
associated with a higher risk of PAD in both high income
countries (HIC) and low to middle income countries (LMIC),
these latter countries representing 73% of global cases. The
236 million PAD cases in 2015 represent a relative increase
of 17% from 202 million in 2010. However, this increase did
not occur evenly in HIC and LMIC. Across five years, the
relative increase was higher in LMIC than in HIC (22.6% vs.
4.5%). It is therefore likely that the observed increase of
prevalent cases in the cohort reported by Schwaneberg
et al.1 in a HIC, is at the lower end of the observed prev-
alence of PAD worldwide, which reinforces their message.
The2017EuropeanSocietyofCardiology (ESC) guidelines on
the diagnosis and treatment of PAD, in collaboration with the
European Society for Vascular Surgery (ESVS), emphasised the1078-5884/ 2019 Published by Elsevier B.V. on behalf of European Society
for Vascular Surgery.
https://doi.org/10.1016/j.ejvs.2019.12.003need to improve the diagnosis of PAD, withmost patients with
PAD being asymptomatic or presenting with atypical symp-
toms, and highlighted the need to assess walking capacity to
detect clinically masked PAD.3 Furthermore, even if asymp-
tomatic, these patients with PAD are at high risk of cardio-
vascular events and should benefit from preventive strategies
and control of risk factors. The ESC/ESVS guidelines recom-
mend ankle brachial index as first line test for PAD screening,
duplex ultrasonography being the first imaging method.3 The
observed rise of PVI in the study by Schwaneberg et al.1 is not
unexpected considering the growing number of patients with
intermittent claudication and compromised daily life activity
despite supervised exercise therapy. It should, however, be
emphasised that data from imaging tests should always be
analysedwith symptoms and haemodynamic data prior to any
intervention.
In the study by Schwaneberg et al.,1 among >200,000
hospitalisations, 49.4% occurred in patients with chronic
limb threatening ischaemia (CLTI) with a high prevalence of
diabetes. To help the clinician, a new classification system
(WIfI) has been proposed as the initial assessment of all
patients with ischaemic rest pain or wounds.4 WIfI stands
for Wound, Ischaemia (based on objective haemodynamic
studies) and foot Infection (from local to systemic since the
benefit of revascularisation is also dependent upon infec-
tion control). The increasing number of PVI together with a
decrease in the number of major amputations as observed
by Schwaneberg et al.1 are encouraging and suggest
appropriate revascularisation of patients with CLTI together
with best medical treatment and risk factor control.
The study from Schwaneberg et al.1 has some obvious
shortcomings. It is a post hoc study of health insurance claims
data of patients with PAD. It is well known that such registries
collected by healthcare providers for billing purposes have a
risk of upcoding comorbidities even if data are cross checked
by independent physicians as it has been the case in Germany.
By contrast, major factors such as smoking may be missed if
they do not have any billing impact. The finding of diabetes as
a decreasing comorbidity in PAD patients is counterintuitive,
given the current epidemics of diabetes and metabolic syn-
drome that are associated with increased rates of PAD.5
But perhaps most importantly, this study lacks granularity
when considering mid and long term outcomes and patient
follow up. The reader would have been interested to know
more about the fate of these PAD patients after PVI,
particularly in the long term.6 Unfortunately, stratified in-
formation about surveillance outcomes after vein bypass or
endovascular treatment is lacking. A consensus document
6 Editorialregarding the follow up of patients after revascularisation
for PAD has recently been published by the ESC working
group on Aorta and Peripheral Vascular Diseases and the
ESVS and would complement this registry by recommending
a standardised follow up emphasising the importance of
multidisciplinary management of these patients with a
clinically reasonable and cost effective strategy.7
However, the efforts of Schwaneberg et al.1 are to be
commended because their study on more than 156,217 pa-
tients is a real life and contemporary picture of PADnot limited
to highly selected patients as in most randomised studies. In
the era of big data, these studies will become more frequent.
Themajor advantages of big data relate to the sheer size of the
data sets, their variety and speed of accumulation. There re-
mains, however, a significant risk of selection bias or bias by
indication when using big data for comparisons of (non-
randomised) diagnostic or therapeutic strategies. A recent
study by Perez et al.8 reporting the results of a large scale
assessment of a smart watch to identify atrial fibrillation in
more than 400,000 participants is an example of a large scale
pragmatic study using user owned connected devices to
assess outcomes, a technology that might also be suitable to
assess functional outcomes in patients with PAD.
In conclusion, Schwaneberg et al.1 reconfirm, in a large
scale study, that PAD is an increasing major public health
challenge in European HIC countries. Other epidemiological
studies have shown that this is also the case elsewhere,
particularly in LMIC countries. With the demographic trend
towards increased ageing and diabetes, an ever greater
increase in the number of patients with PAD is expected in
the future, reinforcing the need for an early diagnostic tool.
The editors of the European Journal of Vascular and
Endovascular Surgery (EJVES) strongly encourage the
reporting of high quality data from other countries, allowing
us to carefully evaluate the evolution of disease patterns
and of the treatments that we offer to our patients.9
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